Nexalin Technology, Inc.
nexalin.comWhat Do They Do?
Develops and sells neurostimulation medical devices and related supplies for medical professionals treating patients with mental health conditions.
10-K for FY2025, filed Mar 25, 2026Nexalin is headquartered, and maintains its base of management and operations, in Houston, Texas. We design and develop innovative…View ↗
Medical professionals in the United States have utilized the Gen-1 device to administer treatment to patients in clinical settings. While…View ↗
While we continue providing services to medical professionals to support patients’ use of the Gen-1 devices which were in operation prior…View ↗
For the years ended December 31, 2025 and 2024, we generated approximately $302,000 and $169,000 respectively, of revenue primarily from…View ↗
Who Are Their Customers?
Medical professionals use Gen-1 in U.S. clinical settings, while Nexalin sells Gen-2 internationally to its distributor; licensing and treatment-fee agreements serve customers using devices in their practices.
10-K for FY2025, filed Mar 25, 2026Medical professionals in the United States have utilized the Gen-1 device to administer treatment to patients in clinical settings. While…View ↗
The Company has existing licensing and treatment fee agreements with its customers for the use of the Nexalin Device in their practices.…View ↗
The Company derives revenues from our license agreements by charging a monthly licensing fee for the duration of the agreement. The Company…View ↗
How Are They Changing?
-
Aug 17, 2026
Nasdaq cited an equity deficiency as another delisting basis
Nexalin said it would present its position at a hearing.
Sources
8-K, filed Aug 17, 2026
On August 14, 2026, Nexalin Technology, Inc. (the “Company”) received a letter (the “Letter”) from the Listing Qualifications Staff (the…View ↗
-
Jul 27, 2026
Nasdaq scheduled Nexalin's securities for delisting
Nexalin appealed the determination, staying suspension pending the panel's decision.
Sources
8-K, filed Jul 27, 2026
On July 24, 2026, the Company received a Staff Determination letter from Nasdaq (the “Delisting Notice”) stating that the Company has not…View ↗
-
May 19, 2026
Nexalin acquired PONM and its digital health platform
The platform supports HALO Clarity and the NeuroCare virtual clinic.
Sources
8-K, filed May 19, 2026
On May 14, 2026, Nexalin Technology, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with…View ↗
Loading...
